REG - Chrysalis Invs Ltd - Results of Capital Raise

Chrysalis InvestmentsAnnouncement

13/12/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211213:nRSM3580Va&default-theme=true

RNS Number : 3580V  Chrysalis Investments Limited  13 December 2021

The information contained in this announcement is restricted and is not for
publication, release or distribution in the United States of America, any
member state of the European Economic Area (other than to professional
investors in Belgium, Denmark, the Republic of Ireland, Luxembourg, the
Netherlands, Norway and Sweden), Canada, Australia, Japan or the Republic of
South Africa.

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulation
(EU) No. 596/2014 as amended by The Market Abuse (Amendment) (EU Exit)
Regulations 2019.

 

13 December 2021

Chrysalis Investments Limited

("Chrysalis" or the "Company")

Result of Capital Raise

 

Further to the Company's announcements on 1 December 2021, Chrysalis
Investments Limited announces that it has raised gross proceeds of £60
million pursuant to the Placing and the PrimaryBid Offer (the "Issue").
Accordingly, under the Issue an aggregate of 25,210,084 new Ordinary Shares
have been issued and allotted conditionally upon admission at a price of 238
pence per Ordinary Share.

The Company is pleased to have had positive engagement with a range of
investors throughout the placing and is grateful for the continued support of
its shareholders, particularly in what has become a more challenging market
environment, in light of recent developments regarding the Omicron variant of
Covid-19.

The Investment Adviser expects to deploy the proceeds of the Issue primarily
to drive the performance of existing portfolio companies via certain follow-on
investments.

Application for Admission

Application has been made for 25,210,084 million New Ordinary Shares to be
admitted to the premium segment of the Official List of the FCA and to trading
on the Main Market of the London Stock Exchange.  It is expected that
admission in respect of the New Ordinary Shares will become effective, and
that dealings in the New Ordinary Shares will commence, at 8.00 a.m. on 15
December 2021.

Total Voting Rights

Following the Placing and PrimaryBid Offer, Chrysalis' issued share capital
will consist of 572,483,160 Ordinary Shares with voting rights in the Company.
This figure may be used by Shareholders in determining the denominator for the
calculation by which they will establish if they are required to notify their
interest in, or a change to their interest in, the Company under the FCA's
Disclosure Guidance and Transparency Rules.

Liberum Capital Limited and Numis Securities Limited acted as Joint
Bookrunners in respect of the Placing.

Capitalised terms shall have the meanings attributed to them in the Prospectus
unless otherwise defined in this announcement.

 For further information please contact:

 

 Maitland Administration (Guernsey) Limited      +44 (0) 1481 749364

 Elaine Smeja

 Jupiter Asset Management                        +44 (0) 20 3817 1325

 Magnus Spence

 Liberum Capital Limited                         +44 (0) 20 3100 2000

 Chris Clarke / Darren Vickers / Owen Matthews

 Numis Securities Limited                        +44 (0) 20 7260 1000

 Nathan Brown / Matt Goss

 

 

IMPORTANT INFORMATION

 

This announcement has been issued by and is the sole responsibility of the
Company. Liberum Capital Limited ("Liberum") and Numis Securities Limited
("Numis" and together with Liberum, the "Joint Bookrunners"), each of which
are authorised and regulated by the Financial Conduct Authority in the United
Kingdom, are acting only for the Company in connection with the matters
described in this announcement and are not acting for or advising any other
person, or treating any other person as its client, in relation thereto and
will not be responsible for providing the regulatory protection afforded to
clients of each of them or advice to any other person in relation to the
matters contained herein. Neither Liberum, Numis nor any of its or their
respective affiliates, directors, officers, employees, advisers or agents
accepts any responsibility or liability whatsoever for this announcement, its
contents or otherwise in connection with it or any other information relating
to the Company, whether written, oral or in a visual or electronic format.

The Joint Bookrunners have not authorised the contents of, or any part of,
this announcement and no liability whatsoever is accepted by the Joint
Bookrunners for the accuracy of any information or opinions contained in this
announcement or for the omission of any information. No representation or
warranty, express or implied, is made by the Joint Bookrunners as to the
accuracy, completeness or verification of the information set out in this
announcement, and nothing contained in this announcement is, or shall be
relied upon as, a promise or representation in this respect, whether as to the
past or the future. The Joint Bookrunners do not assume any responsibility for
its accuracy, completeness or verification and accordingly disclaims, to the
fullest extent permitted by applicable law, any and all liability whether
arising in tort, contract or otherwise which it might otherwise be found to
have in respect of this announcement or any such statement.

This announcement does not constitute or form part of any offer or invitation
to sell or issue, or any solicitation of any offer to purchase or subscribe
for, any Ordinary Shares (i) in any jurisdiction in which such offer,
invitation or solicitation is not authorised; (ii) in any jurisdiction in
which the person making such offer, invitation or solicitation is not
qualified to do so; or (iii) to any person to whom it is unlawful to make such
offer, invitation or solicitation. The distribution of this announcement and
the offer of the Ordinary Shares may be restricted by law. Persons into whose
possession this announcement comes must therefore inform themselves about and
observe any such restrictions. Any failure to comply with these restrictions
may constitute a violation of the securities laws of any such jurisdiction. In
particular, this announcement may not be distributed, forwarded to or
transmitted in, into or from the United States, Australia, Canada, Japan,
South Africa, or any member state of the EEA or to any US person (as defined
under Regulation S of the US Securities Act of 1933, as amended (the "US
Securities Act")) ("US Person"). The Ordinary Shares have not been, and will
not be, registered under the US Securities Act, or under any securities laws
of any state or other jurisdiction of the United States and may not be
offered, sold, resold, transferred or delivered, directly or indirectly, in or
into the United States or to, or for the account or benefit of, any US Person,
except pursuant to an applicable exemption from the registration requirements
of the US Securities Act and in compliance with the securities laws of any
state or other jurisdiction of the United States. Any person within the United
States and any US person who obtains a copy of this announcement must
disregard it. No public offering of the Ordinary Shares is being made in any
jurisdiction. No action has been or will be taken by the Company or the Joint
Bookrunners that would permit the offer of the Ordinary Shares or possession
or distribution of this announcement in any jurisdiction where action for that
purpose is required.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROIDKBBKKBDBBBD